The U.S. Food and Drug Administration (FDA) announced that the type 2 diabetes medication Actos® could increase the risk of bladder cancer in some patients. The announcement is based on the agency’s interim review of an ongoing study.
The FDA reported that patients who took Actos® for longer periods of time had a greater risk of developing bladder cancer. Symptoms include blood in the urine, pain when urinating, urinary tract infection, frequent urge to urinate, back pain and abdominal pain.
Days before the FDA’s announcement, both France and Germany banned the sale of Actos® because of results from a French study that linked the medication to bladder cancer.
The new data about the possible risk of bladder cancer in Actos® patients raises concerns about the safety of thiazolidinedione (TZD) drugs in general.
Just last year, the FDA placed Avandia®, a drug in the same class of medications as Actos®, on restricted use because of an increased risk of heart side effects.
If you or a loved one has a history of Actos® use and has been diagnosed with bladder cancer, contact a defective drug lawyer at Berkowitz and Hanna LLC today.